FDA has not consistently shared information on conflict determinations.
New guidance is needed to enhance transparency.
Advisory committee integrity is crucial for public trust.
Strategic angle: A new review reveals the FDA's shortcomings in disclosing financial conflicts of interest among advisory committee members.
FDA has not consistently shared information on conflict determinations.
New guidance is needed to enhance transparency.
Advisory committee integrity is crucial for public trust.